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The endothelium is nowadays described as an entire organ that regulates various
processes: vascular tone, coagulation, inflammation, and immune cell trafficking, depend-
ing on the vascular site and its specific microenvironment as well as on endothelial
cell-intrinsic mechanisms like epigenetic changes. In this review, we will focus on the
control of the adaptive immune response by the tumor vasculature. In physiological con-
ditions, the endothelium acts as a barrier regulating cell trafficking by specific expression
of adhesion molecules enabling adhesion of immune cells on the vessel, and subsequent
extravasation.This process is also dependent on chemokine and integrin expression, and on
the type of junctions defining the permeability of the endothelium. Endothelial cells can also
regulate immune cell activation. In fact, the endothelial layer can constitute immunological
synapses due to its close interactions with immune cells, and the delivery of co-stimulatory
or co-inhibitory signals. In tumor conditions, the vasculature is characterized by an abnormal
vessel structure and permeability, and by a specific phenotype of endothelial cells. All these
abnormalities lead to a modulation of intra-tumoral immune responses and contribute to
the development of intra-tumoral immunosuppression, which is a major mechanism for pro-
moting the development, progression, and treatment resistance of tumors. The in-depth
analysis of these various abnormalities will help defining novel targets for the development
of anti-tumoral treatments. Furthermore, eventual changes of the endothelial cell pheno-
type identified by plasma biomarkers could secondarily be selected to monitor treatment
efficacy.
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INTRODUCTION
The effects of immunity on tumoral angiogenesis are well-known
for several years, but the description of a modulation of immu-
nity by pro-angiogenic molecules, like vascular endothelial growth
factor (VEGF), is more recent (1). The use of anti-angiogenic
molecules has confirmed this relation, as anti-angiogenic treat-
ments can decrease the infiltration of T-regulatory lymphocytes
(Tregs) and myeloid-derived suppressor cells (MDSCs) and lead
to a Th1-immunity profile (2, 3). Endothelium itself is implied in
the regulation of inflammation and growing evidence may sup-
pose a contribution of tumor endothelium in the development of
intra-tumoral immunosuppression. The link between angiogen-
esis and immunity is of great interest as immunosuppression is
considered as the main mechanism implied in the escape of tumor
from anti-tumor immunity and also to some conventional cancer
therapies (chemotherapy, anti-angiogenic molecules. . .) (4, 5).
INTRA-TUMORAL IMMUNOSUPPRESSION
To allow its development, the tumor has to promote neoangiogen-
esis and escape the immune system, which constitutes major hall-
marks of cancer (6). To suppress immune functions, tumors can
inhibit different stages of the immune response induction. First,
the tumor environment can disrupt dendritic cell (DC) function of
antigen-presenting cells to limit the generation of tumor reactive T
cells (7), via transforming growth factor (TGF-β), interleukin (IL)-
10, macrophage colony-stimulating factor (M-CSF), IL-6, hypoxia,
and lactic acid. VEGF blocks the maturation of DCs. Immature
DCs express intermediate amounts of major histocompatibility
complex (MHC) class I and II and co-stimulatory molecules,
high amounts of co-inhibitory molecules, and immunosuppres-
sive cytokines, thus inducing anergy of effector T cells and expan-
sion of Treg (7). Secondly, homing of T cells and their engraftment
can be impaired in tumors, via the modulation of T cell attracting
chemokines and the induction of a prohibitive tumor vascula-
ture (7). Then, tumors can promote immunosuppressive cells’
induction and infiltration, like Treg and MDSC (8). Tregs are
comprised of natural Tregs, which are thymically derived cells
of FoxP3 lineage, and inducible Tregs, which upregulate FoxP3
expression and are derived in the periphery from naïve CD4+
T-cell precursors under tolerogenic conditions. In cancer, Tregs
can produce suppressive cytokines and secreted molecules, induce
T-cell cytolysis, and modulate the interactions with DCs toward
immunosuppression (9). MDSCs are a heterogeneous population
of activated immature myeloid cells that is characterized by an
increased production of potent suppressors of various T-cell func-
tions, like reactive oxygen and nitrogen species, by an upregulation
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of the expression of arginase and inducible nitric oxide synthase
(10). One mechanism to promote these immunosuppressive pop-
ulations is the secretion by tumor cells of immunosuppressive
products such as prostaglandin E2 (PGE2),VEGF, IL-10, and TGF-
β that favor Treg induction and expansion (9). Recent studies have
precised the role of VEGF, which directly contributes to the expan-
sion of Treg (11), the recruitment of MDSCs, and the inhibition of
DC maturation (12). The secretion of chemokines, like CCL22 and
CCL28, by tumor cells and the microenvironment contribute to
the recruitment of immunosuppressive cells in the tumor (13–16).
Finally, tumors can decrease their MHC I molecule expression, not
to be recognized, or express molecules that induce T-cell cytoly-
sis (FasL, TRAIL) and co-inhibitory molecules (programed death
ligand 1-PD-L1-, PD-L2, B7-H4) (17). They can also induce tol-
erance by promoting the expression of inhibitor co-stimulatory
molecules by T lymphocytes, like PD-1, T-cell immunglobulin
and mucin domain-containing molecule 3 (TIM-3), or cytotoxic
T lymphocyte antigen 4 (CTLA-4) (7).
ENDOTHELIUM AND IMMUNITY
Since several years, endothelium has been considered as a whole
organ with a unique situation, as it communicates both with
the circulating compartment and the tissue (18). Endothelium
exerts many functions from the regulation of vascular tone to
that of inflammation and hemostasis. But endothelial cells (ECs)
display profound heterogeneity depending on their anatomic posi-
tion within the vascular tree. This position is defined by their
embryological origin (19) and exposes endothelial cells to differ-
ent microenvironments (19). The biomechanical parameters, like
shear stress and blood flow, associated to biochemical parameters,
like oxygen content and pH of the blood, chemokines, hormones,
components of the extracellular matrix, regulate the phenotype of
the vasculature (20). Endothelial phenotype is thus also influenced
by environment modifications. Acquisition of new capacities by
resting endothelial cells under these modifications is referred to
as endothelial activation. Resting endothelial cells maintain blood
fluidity, regulate blood flow, control vessel wall permeability, and
quiesce circulating leukocytes (21). But activated endothelium can
be pro-thrombotic, constrictive, and pro-inflammatory in order to
manage a pathological situation.
Immune modulation by the endothelium is favored by the
unique position of ECs, exposing them to T cells during extrava-
sation from the circulation into the tissue or the tumor. Several
steps are implied in the regulation of the immune response by
the endothelium. Immune cells must firstly adhere and cross the
vascular barrier before being effective at the site of inflamma-
tion. Moreover, it has been demonstrated that activated ECs could
present antigens to lymphocytes. Depending on the presence of
various sets of co-stimulatory signals, they could activate memory
cells or anergize naïve T cells (21). Under activation, they could also
produce vasodilators, chemokines, and matricial proteins favoring
the recruitment of inflammatory cells. Variations in the expres-
sion and synthesis of diverse molecules can lead to modifications
in the regulation of leukocyte trafficking and lymphocyte activa-
tion. Acute inflammation results from type I activation responses,
mediated by ligands of heterotrimeric G-protein coupled recep-
tors, or from type II activation by inflammation cytokines (22).
Then, adaptive immunity modulates endothelial cell phenotype to
polarize the inflammatory reaction. Chronic inflammation usu-
ally induces angiogenesis and the formation of tertiary lymphoid
organ (22). In a tumoral context, chronic inflammation promotes
every step of tumorigenesis, from initiation through tumor pro-
motion, all the way to metastatic progression (23). The presence
of tertiary lymphoid organ has been described in several tumor
types as a good prognosis factor (24–26), but the tumor develops
several mechanisms to limit the immune reaction as described in
Section “Intra-tumoral Immunosuppression.”
Tumor vasculature has been described as abnormal, with tortu-
ous, leaky,and immature vessels that are finally less functional (27).
Characteristic phenotypes of tumor endothelium have also been
described and some studies identified markers specific of tumor
endothelial cells (TECs) (28–33). Tumor vasculature abnormali-
ties results from the imbalance between pro- and anti-angiogenic
factors in the specific microenvironment to which it is exposed,
usually described as hypoxic, rich in VEGF and other growth
factors, with irregular blood flow (27). However, tumor microen-
vironments are heterogeneous among tumor types and the stages
of development, and different mechanisms could be implied in
the regulation of the immuno-modulating phenotype of TECs. In
this review, we will focus on the changes in tumor endothelium
phenotype that have been or could be implicated in the suppres-
sion of the intra-tumoral adaptive immunity and the mechanisms
controlling them when they have been described.
CONTROL OF INTRA-TUMORAL LYMPHOCYTE INFILTRATION
BY ENDOTHELIAL CELLS
Briefly, rolling of leukocytes occurs by the interaction between
the selectins expressed by leukocytes and their ligands on ECs
(21). Then, leukocyte integrin activation permits its binding to
its adhesion ligand expressed by the endothelium. Finally, leuko-
cyte infiltration depends on the chemokine gradient and the type
of junctions between ECs (21). As observed in physiological and
pathological conditions, ECs can differentially express leukocyte
adhesion molecules. Resting ECs lack surface molecules that can
initiate tethering, under the control of nitric oxide (NO) and other
anti-inflammatory molecules secreted by ECs (34). Maintenance
of adherens and of tight junctions in resting EC may further restrict
transendothelial leukocyte passage (34). Under different mech-
anisms – cell interaction or cytokine effect – the expression of
adhesion molecules and the synthesis of chemokines are upregu-
lated (34, 35). The prohibitive nature of the tumor endothelium
can be mediated by the type and levels of adhesion molecules
expressed and must be maintained by local soluble tumor fac-
tors (36). The mechanisms reviewed in this part are presented in
Figure 1.
DECREASE OF CELL ADHESION MOLECULES
In human solid tumors, a decreased expression of cell adhe-
sion molecules (CAMs) on the vasculature has been described,
impairing the development of an efficient leukocyte infiltration
in tumors. The high level of tumor necrosis factor α (TNF-α)
found in tumors, like in inflammatory responses, should upregu-
late CAM expression on ECs. But tumor microenvironment may
deliver other products that exert a negative regulation. Indeed,
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FIGURE 1 | Control of intra-tumoral immune cell trafficking by tumor
endothelial cells. T-cell trafficking is reduced in tumors despite the
secretion of TNF-α. Pro-angiogenic factors present in the tumor
microenvironment decrease the expression and/or gathering of adhesion
molecules on TECs, and thus T-cell intra-tumoral infiltration. TECs can also
express molecules specific of Treg adhesion and transmigration, thus
promoting anti-tumoral immune suppression.
Griffioen et al. observed a decrease of TEC activation under expo-
sure to pro-inflammatory cytokines, like TNF-α, that could be
attributed to angiogenic factors highly expressed in tumors, basic
fibroblast growth factor (b-FGF), or VEGF. The slightest activa-
tion was characterized by a limited increase of intercellular cell
adhesion molecule-1 (ICAM-1) and 2 (ICAM-2), vascular cell
adhesion molecule-1 (VCAM-1), and E-selectin expression, and
a decreased in vitro adhesion of leukocytes (37). The NO pathway
seems to be implicated in the effect of VEGF on lymphocyte–
endothelium interactions. In resting ECs, a basal production of
NO actively inhibits leukocyte adhesion and activation, by reduc-
ing the expression of important adhesion molecules like P-selectin,
ICAM-1, and VCAM-1, and maintaining adherens and tight junc-
tions (38). Conversely, NO antagonists can abrogate the dereg-
ulation of CAMs induced by VEGF or endothelin-1 (ET-1) and
restore T-cell adhesion (39, 40). Bouzin et al. demonstrated that
VEGF did not influence the abundance of CAMs at the cell sur-
face, but decreased the expression of caveolin-1 via stimulation of
NO pathway, leading to a defect in ICAM-1 and VCAM-1 cluster-
ing at the EC surface (40), which is implicated in transendothelial
migration (41).
Other molecules have been shown to decrease CAM expres-
sion, like epidermal growth factor-like domain 7 (Egfl7) and
endothelin-1. Egfl7 also known as Vascular Endothelial–statin gene
is mostly expressed in ECs and endothelial progenitors during
embryonic and neonatal development. Egfl7 regulates vascular
integrity and smooth muscle cell migration (42). An upregula-
tion of egfl7 expression has been observed in ECs during vascular
remodeling, such as in reproductive organs during pregnancy, in
regenerating endothelium following arterial injury, in atheroscle-
rotic plaques, and in growing tumors (42, 43). Its expression was
thought specific of ECs but has also been detected in tumor cells
(44). In tumors, levels of Egfl7 are correlated with markers of
metastasis and with poor prognosis (45). In glioma, Egfl7 lev-
els correlate with tumor grade (46). Egfl7 can promote tumor
growth by repressing ICAM-1 and VCAM-1 expression, then lim-
iting immune cell infiltration, as observed in breast and lung
carcinoma murine models (44). Endothelins and their receptors
are over-expressed in high-grade glioma, colon cancer, and breast
cancer in humans (44). ET-1 is produced by endothelial cells and
has a strong vasoconstrictive effect on smooth muscle cells via
the endothelin A receptor. But ET-1 induces vasodilatation when
binding on the endothelin B receptor [ET(B)R] expressed by the
endothelium via induction of nitric oxide secretion. Endothelins
also regulate multiple aspects of angiogenesis (47). Indeed, a stim-
ulatory interaction between VEGF and ET-1 has been described on
each gene expression (48). ET-1 synthesis is induced by hypoxia,
shear stress, and ischemia (21) and ET-1 can promote VEGF secre-
tion by tumor cells (49–51). An overexpression of ET(B)R by TECs
has been associated with a decreased ICAM-1 expression and an
absence of tumor-infiltrating lymphocytes (TILs), and identified
as a poor prognosis marker (39). As for VEGF, NO antagonists can
abrogate the deregulation of CAMs induced by ET-1 and restore
T-cell adhesion (42).
INHIBITION BY SOLUBLE CELL ADHESION MOLECULES
A competitive binding of soluble adhesion molecules could also
be hypothesized to explain the decrease in leukocyte infiltration.
Endoglin, an auxiliary receptor of the TGF-β family of proteins
essential for angiogenesis, is predominantly expressed in vascular
ECs (52). Endoglin haploinsufficiency is responsible for heredi-
tary hemorrhagic telangiectasia type 1, characterized by telang-
iectases and arteriovenous malformations (53). A high expression
of endoglin would be a potent marker of solid tumor vasculature
(52). Recently, endoglin has been involved in leukocyte trafficking
by interacting with α5β1 integrin (VLA-5) expressed on leukocytes
(54). In the same study, an inhibition of leukocyte adhesion by sol-
uble endoglin was observed. The soluble form of endoglin could
be involved in the suppression of anti-tumor immune response as
increased levels in serum and plasma from cancer patients have
been reported as a marker of poor prognosis (55, 56).
CD146, also known as melanoma cell adhesion molecule
(MCAM) or S-Endo-1 antigen, is a component of the endothe-
lial junction involved in the control of cell cohesion and tumor
angiogenesis (57). CD146 is expressed by ECs but also by several
types of cancer cells, smooth muscle cells, follicular DCs and has
been described on activated lymphocytes and perivascular cells.
As for endoglin, a soluble form of CD146 has been described, with
chemotactic and angiogenic properties (58). The role of CD146 in
tumors needs to be further defined. Indeed, both membrane and
soluble forms of CD146 are involved in monocyte and lymphocyte
trafficking (59, 60). However, soluble CD146 can induce VEGFR2
and VEGF expression in a model of hind-limb ischemia, thus
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promoting angiogenesis (58). The angiogenic role of membrane
and soluble CD146 seems predominant, as AA98 antibody directed
against CD146 can inhibit tumor growth in xenograft mice (61).
Poor data are available on the level of soluble CD146 in tumors,
which could be implied in a decrease of lymphocyte infiltration in
tumors, either directly or throughout VEGF expression induction.
EXPRESSION OF SELECTIVE CELL ADHESION MOLECULES
Another way to decrease anti-tumoral immunity is the expression
of adhesion molecules favoring specific intra-tumoral infiltra-
tion of immunosuppressive populations. For example, tumor-
associated vessels in hepatocellular carcinoma present an increased
level of common lymphatic endothelial and vascular endothelial
receptor-1 (CLEVER-1). This recycling and intracellular traffick-
ing receptor has been implicated preferentially in transendothelial
migration of CD4+ FoxP3+ regulatory T cells (62). Its expres-
sion seems to be organ-specific and is enhanced by hepatocyte
growth factor but not by classical pro-inflammatory cytokines. A
selective recruitment of Treg has been observed in tumor tissue
of human pancreatic carcinoma due to an increased expression
of a broad variety of T-cell transmigration-relevant addressins
on tumor endothelium: E-selectin, ICAM-1 and -2, MAdCAM-1
(mucosal vascular addressin cell adhesion molecule-1), VCAM-
1, or CD166 (63). Addressin expression on TECs has also been
described to be modulated by tumor-derived factors and may vary
depending on tumor microenvironment.
CONTROL OF ANTI-TUMORAL LYMPHOCYTE REACTIVITY
Two signals are required for induction of cell proliferation and
cytokine production in resting T cells. Occupancy of the T-cell
receptor (TCR) by antigen presented by the MHC delivers the
first signal to the T cell, while the second signal is provided
by the interaction with co-stimulatory ligands on APCs. For-
mation of an immune synapse may serve to stabilize adhesion
and extend the duration of bidirectional signaling between the
APC and the T cell. Immune synapses are constituted by a con-
centration of adhesion molecules at the edge, while TCR/MHC
complexes and co-stimulatory molecules are grouped in the center.
A modulation in MHC II, co-stimulatory/co-inhibitory molecule,
or cytokine expression by TECs could participate to the tumor-
induced immunosuppression. The major mechanisms reviewed
in this part are presented in Figure 2. Some of them have been
described in tumors; others exist in physiologic or pathologic
conditions and could participate in tumoral immunotolerance.
ANTIGEN PRESENTATION
Antigen-presenting cell function of TECs is defined by their capac-
ity to present exogenous antigens by class II MHC. The anti-
gen uptake, processing, and presentation are regulated by the
microenvironment as pro-inflammatory cytokines like TNF-α and
interferon-γ (IFN-γ) can upregulate the expression of class II
MHC and accessory molecules (34). The ability of ECs to enhance
memory T-cell activation is well-established, and has been attrib-
uted to the presence of both MHC and co-stimulatory molecules
on ECs (64, 65). Adhesion molecules are involved in the formation
of immunological synapses, which need the same docking struc-
tures than required for transendothelial migration (34). Modula-
tion of the expression of adhesion molecules will then influence the
FIGURE 2 | Suppression of anti-tumoralT-cell activity. TECs can
suppress anti-tumoral adaptive immunity by inducing T-cell anergy or death.
This suppression can result either from a cell contact negative signal as
TECs can express co-inhibitory molecules, or from inhibitory cytokines
secreted by TECs. Various other mechanisms can lead to T-cell activity
inhibition, like antigen presentation by the mannose receptor (mannose R)
or the expression of IDO.
regulation of lymphocyte reactivity by TECs. The consequence of
antigen presentation by TECs will finally also depend on the type
of co-stimulatory signals interacting with T cells.
Other mechanisms of exogenous antigen intake have been
described in tumors, leading either to favor or to limit anti-tumor
immunity. Indeed, tumor antigen peptide transfer in TECs has
been observed in vitro (66). Formation of gap junctions between
melanoma cells and ECs led to a transfer of tumor peptides and to a
specific killing of tumor-surrounding cells by autologous cytotoxic
T lymphocytes (66). This mechanism should favor anti-tumor
immunity but co-stimulatory signals may be modulated upon
tumor microenvironment. Conversely, antigen uptake, processing,
and presentation to T cells by liver sinusoidal ECs via the mannose
receptor (67) have been suggested to limit local immune response
in the liver (68). In a model of colon carcinoma, tumor cell inter-
action with liver sinusoidal endothelium through ICAM-1 led to
a cyclo-oxygenase 2-dependent IL-1 production, which upregu-
lated the expression of mannose receptor on TECs and decreased
anti-tumor activity of interacting lymphocytes (69).
CO-STIMULATORY SIGNALS
The costimulation necessary to activate resting T cells may be
mediated by three types of molecules: signaling molecules (true co-
stimulators), adhesion molecules, and activating cytokines. Tumor
microenvironment controls T-lymphocyte activation by several
mechanisms, among them the inhibition of DC maturation.
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Indeed, immature DCs express intermediate amounts of MHC
class I and II and co-stimulatory molecules, high amounts of
co-inhibitory molecules, and immunosuppressive cytokines, thus
inducing anergy of effector T cells and expansion of Treg. The
tumor microenvironment also induces the expression of co-
inhibitory molecules on T lymphocytes that interact with their
ligands expressed on tumor cells. Interestingly, TECs can also
express co-inhibitory molecules and produce immunosuppressive
molecules,and thus may participate to anergize T cells in the tumor
microenvironment.
Surface co-stimulatory molecules
Human ECs cultured from different vessel sources express
numerous co-stimulatory molecules, including LFA-3, OX40-L,
4-1BB-L (CD137), ICOS-L, and glucocorticoid-induced TNF-
receptor-related protein (GITR-L) (70). Among the activating
co-stimulatory signals, human endothelial costimulation of T cells
can be attributed in large part to LFA-3, which binds to CD2 on
human T cells (71). Human ECs constitutively do not generally
express either CD80 or CD86, with some possible exceptions (34).
They express CD40, often described as a co-stimulator of T-cell
activation, although it is uncertain if engagement of the CD40
ligand on T cells actually delivers a co-stimulatory signal to the
T cell (70).
Among co-inhibitory molecules, ECs can express PD-L1, which
bind to PD-1 on activated lymphocytes and down-regulate T-cell
activation (72). Like many other co-signaling molecules, PD-L
expression is upregulated by pro-inflammatory cytokines like IFN-
γ (73). Conversely, signaling by PD-L pathway led to inhibition
of IFN-γ secretion and CD8 cytolytic activity in response to EC
antigen presentation (73). Liver sinusoidal ECs can present soluble
antigens like carcinoembryonic antigen from colorectal carcinoma
together with the co-inhibitory molecule PD-L1, thus promot-
ing tolerance of CD8+ T cells (74). An overexpression of B7-H3
(CD276) on tumor cells has been reported in selected cancers
with both stimulatory and inhibitory properties (75). However,
B7-H3 expression by the tumor vasculature seems to be a marker
of poor prognosis in renal cell carcinoma (76), ovarian carcino-
mas (77), and endometrial cancers (78). In renal cell carcinoma,
an expression of B7-H4, a negative co-stimulatory molecule, has
been reported to be associated with cancer progression (79, 80).
Expression of B7-H4 by the vasculature was hardly specific to
TECs in human renal cell carcinoma compared to adjacent renal
tissue vessels (79). A preferential expression of another negative
co-inhibitory molecule, TIM-3, has been observed on the endothe-
lium from B-cell lymphoma, with a level of expression closely
correlated to dissemination and poor prognosis (81). In addition,
FasL expression on TECs could contribute to limit anti-tumoral
immunity as it inhibits leukocyte extravasation through apopto-
sis induction (82). The high levels of endothelial FasL expres-
sion in gliomas, together with the inverse correlation observed
between FasL expression and CD8+/CD4+ T cells infiltration
ratios, indeed suggested that FasL could decrease T-cell infiltration
in brain tumors in a subset-selective manner, thus contributing to
glioma immune privilege (83).
The decrease of activating co-stimulatory molecules expressed
by ECs could be hypothesized but have not been reported.
Molecules involved in the direct stimulation of lymphocytes like
ICOS-L, CD40, CD80, CD86 are upregulated by angiostatic mol-
ecules and Th1 cytokines. An inhibition of these co-stimulatory
signals has also been proposed after the identification of markers
of tumor endothelium by Seaman et al. (28). Among them, CD137,
also called 4-1BB, is a glycoprotein usually expressed by activated
T, B and NK cells, DCs, and bone marrow myeloid precursors, and
is involved in T-cell co-stimulation. Its expression is undetectable
in normal vessels (84) and can be induced by hypoxia (85). TECs
seem to specifically express both a membrane-bound form of the
molecule and a soluble one (28). Although the exact functions of
each of these forms are unclear, soluble CD137 is thought to be
antagonistic to the co-stimulatory activity of membrane-bound
CD137 on T cells. Thus, sCD137 secreted by TECs may reduce
immune activity against tumors. As activation of CD137 on EC
induces adhesion molecule expression, like ICAM-1, VCAM-1,
and E-selectin (85), high levels of sCD137 could also limit this
process.
Another mechanism involving the immunological synapse has
been described in tumors. CD31, or platelet endothelial cell adhe-
sion molecule-1 (PECAM-1), can form endothelial junctions and
promote leukocyte transendothelial cell migration, respectively
(41). But it is also involved in the interactions between T lym-
phocytes and APC and seems to participate to tumoral immuno-
suppression. Indeed, a lack of CD31 expression in vivo amplified
cancer T-cell-mediated rejection, in association with an increase
of the threshold of TCR signaling required, leading to a resistance
to tolerance induction (86).
Soluble and intracellular molecules
Under pro-inflammatory signals, ECs can secrete cytokines and
directly activate resting effector cells (34). Some act as mitogens or
activators, like IL-1 and IL-15, others influence the differentiation
of activated T cells, like IL-6, IL-11, IL-12, and IL-18. GITR-L and
IL-6 can also down-regulate Treg activity.
In tumors, immunosuppressive cytokines can be secreted under
the tumor microenvironment stimuli. Studies investigating the
effect of conditioned media from Lewis lung carcinoma (87) and
oral squamous cell carcinoma (88) on ECs observed an increased
level of PGE2 and VEGF in the culture supernatants that dis-
rupt NK cell, T-cell, and macrophage functions. High secretions
of PGE2, IL-6, TGF-β, and VEGF and a decrease secretion of
IL-12 have been observed in ECs isolated from a mouse model
of Lewis lung carcinoma (89). Conditioned media from these
ECs disrupted T-cell cytokine production in response to anti-
CD3 stimulation, and had a decreased ability to activate NK
cells and induce macrophage phagocytosis (89). In vitro, interac-
tions between microvessel ECs and tumor cells from head and
neck squamous cell carcinoma induced the secretion of PGE2
by ECs through an IL-1 pathway (90). Taflin demonstrated in
an experimental model of microvascular endothelium that ECs
could induce Th17 lymphocytes via IL-6 endothelial synthesis
(91). Recently, the prevalence of Th17 cells was found to be
elevated in peripheral blood of head and neck squamous cell car-
cinoma patients. In addition, tumor tissue and tumor-draining
lymph nodes were infiltrated by a huge number of Th17 cells
representing an important fraction of the TILs (92). Th17 cells
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are subpopulations of CD4+ T cells favoring the recruitment
of neutrophils and the induction of pro-inflammatory cytokines
(IL-1, IL-6, TNF-α . . .) (93). Some of these Th17 cells express
immunosuppressive enzymes (CD39, CD73) (94). Their role on
the control of tumor is ambivalent, as they can promote the growth
of tumor cells via the induction of an inflammatory state in the
tumor microenvironment and an increase of angiogenesis (95, 96).
But other studies reported an inhibitory role of these cells via the
expansion of anti-tumor CD8+ T cells (97).
In DCs, the interaction between CTLA-4 and CD80/CD86
induces indoleamine 2,3-dioxygenase (IDO) expression. This
inflammatory enzyme is implicated in the catabolism of the essen-
tial amino acid tryptophan and participates in immune tolerance
and tumor immunoresistance by simultaneously depleting essen-
tial tryptophan and generating immunosuppressive tryptophan
metabolites. IDO expression is a mechanism to regulate T-cell acti-
vation by APCs and has been considered to be a major mechanism
involved in the escape of tumors from the host immune response
(98). IDO expression by ECs has been described in tumors but
its role is not clearly defined. A study of Batista et al. described
endothelial IDO expression specifically in high-grade tumors and
not in low-grade (99). However, in renal cell cancer, IDO expres-
sion was found nearly specific of ECs from newly formed blood
vessels (100) and inversely correlated with the content of prolif-
erating Ki-67+ tumor cells in primary and metastatic clear cell
RCC (100). In this tumor, expression of IDO by tumor cells might
restrict tumor growth by limiting the influx of tryptophan from
the blood to the tumor or generate tumor-toxic metabolites. The
role of IDO needs then to be clarified.
REVERSAL OF ENDOTHELIAL BARRIER: CLINICAL
APPLICATIONS
Tumor infiltration by lymphocytes depends on cancer cell type
and individuals but is a prognostic factor of response to treat-
ment. A recent Nature Cancer Review meta-analysis summarizes
the impact of different immune cells on clinical outcome from
more than 120 published articles (101). A strong T-cell infiltration
associated with good clinical outcome was reported in many differ-
ent tumors. Establishment of an immunoscore that would include
the immune cell density, calculated by numerical quantification of
two lymphocyte populations, cytotoxic and memory T cells at the
center of the tumor and the invasive margin of tumors, has thus
been proposed (102). The level of TILs can also be useful to adapt
the treatment. Indeed, in tumors with high levels of TILs, intra-
tumoral immunosuppressive mechanisms must be attenuated. In
tumors with low levels of TILs, either tumor antigen-presenting
process is down-regulated, or the prohibitive tumor endothelial
barrier enables T cells to home to tumors, or both. Associa-
tion between endothelium targeted therapy and immunization
boost like vaccination or cell adoptive transfer could enhance
anti-tumoral immune response.
REVERSAL OF IMMUNOSUPPRESSION BY ANTI-ANGIOGENIC THERAPY
Vascular endothelial growth factor-targeted therapies were ini-
tially developed in order to inhibit new blood vessel growth
and thus starve tumors of necessary oxygen and nutrients. It
has become increasingly apparent, however, that the therapeutic
benefit associated with VEGF-targeted therapy was complex,
probably involving multiple mechanisms, some of them relying
on the improvement of the immune status during tumor develop-
ment. An increase of B and T cells has been observed in patients
with metastatic colorectal cancer treated with bevacizumab, an
antibody directed against VEGF (103). This treatment can also
promote the differentiation of DCs with a parallel decrease of
the immature myeloid cell population in different tumors (104).
A decrease of different subsets of immunosuppressive cells, like
MDSCs and Tregs, has also been described under sunitinib treat-
ment in metastatic renal cell carcinoma (2, 3), in association with
a reversal of type 1 T-cell suppression (3, 105, 106).
The clinical benefit observed on tumor growth made several
molecules indicated in first line treatment of renal cell carcinoma
and colorectal cancer, in association with chemotherapy. Despite
their impact on immunosuppression, no benefit on overall sur-
vival has been observed with anti-angiogenic therapies used in
monotherapy. These limited results might be explained by the exis-
tence of a therapeutic window for their benefit. Indeed, vascular
normalization has been observed under anti-angiogenic treat-
ment, with a more mature and functional tumor vasculature able
to deliver chemotherapy or immune cells (107–109). However,
this effect has been demonstrated to be transient, as prolonged
anti-angiogenic treatments finally lead to vasculature rarefaction
(110). Combinations between anti-angiogenic therapy and anti-
tumoral vaccination are now in clinical development (111) and
have already shown promising results in preclinical models (8,
112, 113). A stronger effect of vaccination when associated with
sunitinib in a mouse model has been observed, with an increase of
CD8+T-cell infiltration, a decrease in Treg and MDSC infiltration,
and a slower tumor growth (113). Bose et al. also demonstrated the
benefit of associating vaccination and sunitinib, where the increase
of lymphocyte infiltration was associated to vascular normaliza-
tion and an increase in the expression of adhesion molecules by
TECs (114). As anti-angiogenic therapies also modulate periph-
eral immune populations, the validation of immune parameters
as predictive biomarkers of the effect of anti-angiogenic therapy
would be of great interest. To face the difficulty to optimize the
anti-angiogenic treatment to reach a strong adjuvant effect, tools
to induce stable normalization have been proposed, like targeting
gene involved in abnormal vascular development like PHD2 (115)
or regulator of G-protein signaling 5 (107), or correcting oxygen
tension by inositol trispyrophosphate (116).
REVERSAL OF ENDOTHELIAL CELL ANERGY
Blocking more specifically immune suppressive ECs may help
improving the efficacy of existing immunotherapies, particularly
those consisting of T cells or NK cells as these cells must pass
through the tumor vasculature to infiltrate tumors. Interestingly,
EC anergy induced by tumor pro-angiogenic factors (Figure 1)
can be reversed under high dose of TNF-α (117). The treat-
ment of mice with NGR–TNF-α, a fusion form of TNF-α with
a tumor-homing peptide recognizing specifically TECs, induced
intra-tumor upregulation of CAMs, and the infiltration of tumor-
specific effector CD8+ T cells. Activation of specific molecules
expressed by ECs known to induce immune reactivity has also
proved to be beneficial. Use of agonists of CD137, a co-stimulatory
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molecule identified as a tumor endothelium marker by Seaman
et al. (28), or of multivalent RNA aptamers binding CD137 have
been shown to enhance anti-tumor CD8 T-cell-mediated immu-
nity in mice (118–120). The therapeutic effects of anti-CD137
agonist antibodies on tumors could be explained by comple-
mentary mechanisms, with activation of both immune cells and
endothelium. Indeed, they can promote CAMs expression by ECs
and then T-cell infiltration, but no effect on angiogenesis or vas-
culogenesis has been observed (85). Combination of anti-CD137
antibodies with other immunotherapeutic strategies (121–123)
and conventional therapies (124) also revealed successful in mouse
models.
CONCLUSION
Regulation of immunity is one of the numerous functions of
endothelium. It is now well-demonstrated that tumor endothe-
lium is implicated in the suppression of adaptive anti-tumoral
immune response exerted by the tumor. Tumor endothelium is
a prohibitive barrier that inhibits T-cell homing to the tumor
and inactivates immune cells through antigen presentation co-
inhibitory signals and the expression of immunosuppressive mol-
ecules. The immunosuppressive phenotype of TECs is dependent
on the tumor microenvironment. The regulation of immunity by
tumor vasculature was initially demonstrated by the reversal of
immunosuppression observed under anti-angiogenic treatments.
Combination between immunotherapies and these treatments
reversing TEC phenotype have shown encouraging results pro-
moting the use of these molecules as adjuvant therapies. For that
purpose, validation of immune parameters as predictive biomark-
ers is required. Alternative tools inducing stable normalization
are also in development. Further research is needed to iden-
tify new endothelial targets and determine how the modulation
of EC phenotype could be combined with immunotherapeutic
strategies.
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